Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Ethylisothiourea. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 5/20 | 0.75 |
| ▸ | NOS1 | P29475 | 5/20 | 0.75 |
| ▸ | NOS3 | P29474 | 4/20 | 0.75 |
| ▸ | NOS2 | P35228 | 4/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylisothiourea SCHEMBL11693925 | 0.89 | NOS1 (0.65) | CYP2C19NOS1NOS3NOS2CYP1A2 | |
| Ethylisothiourea SCHEMBL160501 | 0.87 | — | — | |
| Ethylisothiourea SCHEMBL2916536 | 0.84 | — | — | |
| Ethylisothiourea SCHEMBL18169 | 0.84 | — | — | |
| Ethylisothiourea SCHEMBL6837679 | 0.84 | — | — | |
| Ethylisothiourea SCHEMBL16322930 | 0.81 | — | — | |
| Ethylisothiourea SCHEMBL7418298 | 0.81 | — | — | |
| Sulfuric Acid SCHEMBL11698488 | 0.81 | NOS1 (0.77) | CYP2C19NOS1NOS3NOS2CYP1A2 | |
| Ethylisothiourea SCHEMBL2787239 | 0.80 | NOS1 (0.75) | CYP2C19NOS1NOS3NOS2CYP1A2 | |
| Ethylisothiourea SCHEMBL31563742 | 0.75 | NOS1 (0.75) | CYP2C19NOS1NOS3NOS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462497-A | Pyridopyrimidinone Process for the preparation of compounds | 上海皓元医药股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-20040220242-A1 | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| US-20040220113-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| CN-119896762-A | Process monitoring device | 舒万诺知识产权公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119462497-A | Pyridopyrimidinone Process for the preparation of compounds | 上海皓元医药股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240024518-A1 | CONTRAST AGENT AND PRECURSOR AND MANUFACTURING METHOD THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2024-01-25 | — | — | US | disclosed |
| US-11596704-B2 | Process monitoring device | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-03-07 | — | — | US | disclosed |
| US-10792383-B2 | Method of disinfecting a medical device | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3551237-A1 | PROCESS MONITORING DEVICE | 3M Innovative Properties Company (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190105416-A1 | METHOD OF DISINFECTING A MEDICAL DEVICE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-04-11 | — | — | US | disclosed |
| EP-3461811-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M Innovative Properties Co. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20160096802-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2016-04-07 | — | — | US | disclosed |
| WO-2014204763-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20090298747-A1 | Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions | BIO HOLDING, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20070224671-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20040220239-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220242-A1 | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220113-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | disclosed |
| US-6489308-B1 | ONE AGENT EXHIBITING MAMMALIAN ALPHA 1-ANTITRYPSIN OR ALPHA 1-ANTITRYPSIN-LIKE ACTIVITY, AND A FREE RADICAL SCAVENGER SUCH AS 2,6,8-TRIHYDROXYPURINE, DIHYDRORHODAMINE, OR A COMBINATION THEREOF | TRUSTEES OF UNIVERSITY OF TECHNOLOGY CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-4046884-A | N-(α-Aminoalkylidene)phosphor- and phosphonamidates, and method for controlling insects | VELSICOL CHEMICAL CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792383-B2 | Method of disinfecting a medical device | FANCI, ALDH7A1, DAO | CYP2C19 255/4885NOS1 1088/4885NOS3 970/4885 |
| US-20240024518-A1 | CONTRAST AGENT AND PRECURSOR AND MANUFACTURING METHOD THEREOF | TNNT2, NPPA, VHL | CYP2C19 3809/4885NOS1 2506/4885NOS3 2949/4885 |
| US-20160096802-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | GMPS, GUCY1B2, GUCY1A1 | CYP2C19 866/4885NOS1 50/4885NOS3 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.